
How Abu Dhabi's salt domes could help the UAE reach its net-zero targets
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Arabian Post
13 hours ago
- Arabian Post
Life Sciences on the Chinese Mainland – Vital signs: Diagnosing trends in the life sciences real estate market on the Chinese mainland
HONG KONG SAR – Media OutReach Newswire – 1 August 2025 –Cushman & Wakefield, a leading global real estate services firm, today released itsreport. It is based on in-depth interview surveys we conducted on professionals active in the life sciences sector on the Chinese mainland. The life sciences industry on the Chinese mainland is undergoing a transformative phase, driven by progressive policies, groundbreaking innovations, the emergence of influential life sciences companies, and strategic regional development. This report delves into the latest trends shaping the sector. Policy Landscape – National and Local Catalysts Reforms enacted in 2024-2025 have significantly accelerated sector development. Nationally, China relaxed restrictions on foreign investment in gene and cell therapy and allowed the establishment of wholly foreign-owned hospitals in key cities. Regulatory incentives – such as data protection and marketing exclusivity – have improved market access for innovative drugs. Locally, cities like Beijing, Shanghai, Shenzhen, Guangzhou, and Suzhou are rolling out targeted subsidies, fast-track approvals, and ecosystem-building programmes that directly benefit biotech development. ADVERTISEMENT Recent national policy initiatives on the Chinese mainland Types of policies Detail information Opening to Foreign Investment In 2024, China eased restrictions on foreign investments in stem cell research, gene therapy, and genetic diagnostics within Free Trade Zones (FTZs) like Beijing, Shanghai, Guangdong, and Hainan. Regulatory Incentives The State Council's Circular No. 53 introduced measures such as regulatory data protection and marketing exclusivity for select pharmaceutical products, including orphan and paediatric drugs. Wholly Foreign-Owned Hospitals China now permits the establishment of wholly foreign-owned hospitals in cities like Beijing, Shanghai, and Shenzhen, enhancing healthcare services and encouraging foreign investment. Source: Cushman & Wakefield Research Industry Innovation and Company Growth Chinese life sciences companies are moving beyond generic drug manufacturing toward innovative therapies. Firms like Akeso, BeiGene, Gracell, and Legend Biotech are now global players, leading in CAR-T, bispecific antibodies, and AI-assisted R&D. These companies are not only commercialising cutting-edge treatments but also attracting international investment and licensing agreements, reinforcing the Chinese mainland's global relevance in life sciences. Real Estate Development and Regional Hubs ADVERTISEMENT Innovation hubs such as Suzhou BioBAY, Zhangjiang Hi-Tech Park (Shanghai), and the Bioisland Innovation Centre (Guangdong) are central to regional clustering. These hubs offer end-to-end support, including shared labs, venture capital access, GMP-compliant facilities, and proximity to academic and clinical networks. The rise of second-tier innovation cities like Chengdu and Ningbo further expands growth corridors. The 'R&D + Manufacturing + Service' ecosystem Source: Cushman & Wakefield Research Landlord Perspectives – Evolving Real Estate Models Real estate developers and landlords are adapting to sector-specific requirements through asset-light models, flexible leasing, and high-specification lab and production space. Tier-1 cities face saturation, but central and western regions exhibit healthy demand. Developers are incorporating advanced sustainability and compliance features to meet growing regulatory and ESG expectations, particularly in GMP and cleanroom environments. Digitalisation, environmental policies, and differentiated tenant strategies are shaping performance. Operators now focus on integrated ecosystems with platforms that link tenants to R&D services, policy benefits, and technology partners. Occupier Perspectives – Growth, Innovation, and Challenges Life sciences occupiers are navigating regulatory reform, rising compliance demands, and intensified market competition. Many are localising production and R&D, leveraging regional subsidies, and investing in AI-powered innovation platforms. Occupiers seek flexibility, proximity to talent and infrastructure, and co-located R&D and manufacturing to support accelerated innovation and operational agility. In real estate, demand is strongest for GMP-certified labs, modular production facilities, and shared innovation platforms. Occupiers emphasise location advantages, sustainability certifications (e.g., LEED, WELL), and integration into clusters that enable faster time-to-market. Tony Su, Managing Director, National Head of Industrial & Logistics Property Services, China, said, 'Life sciences business parks on the Chinese mainland demonstrated clear regional differentiation, highlighting opportunities for strategic positioning. While Tier-1 cities saw more moderate performance due to broader macroeconomic factors and abundant supply, core cities in central and western regions recorded healthy occupancy rates, underpinned by strong industrial clustering and increasingly sophisticated ecosystems – contributing to steady growth in asset value.' Johnathan Wei, President, Project & Occupier Services, China, said, 'Several interviewed life sciences companies on the Chinese mainland achieved revenue growth supported by innovative products and favourable policy tailwinds. While overall growth remained modest for many, a select group reported strong performance, highlighting opportunities for differentiation'. Andrew Chan, Managing Director, Head of Valuation & Advisory Services, Greater China, said,' Looking ahead to 2025 and beyond, growth opportunities lie in AI-driven drug discovery, personalised medicine, advanced therapeutics (CGT, RNA), and green-certified facilities. Government policies continue to support innovation through fast-track approvals, rare disease funding, and subsidies aligned with dual-carbon and ESG goals'. Shaun Brodie, Head of Research Content, Greater China, 'Life sciences real estate is shifting from generic parks to specialised, digitally enabled campuses with high compliance and flexibility. Investment strategies increasingly emphasise long-term partnerships, collaborative operating models, and digital infrastructure. Both landlords and occupiers express cautious optimism, with strategic differentiation and regional targeting seen as keys to unlocking future value'. Please click here to download the full report. Hashtag: #Cushman&Wakefield The issuer is solely responsible for the content of this announcement. About Cushman & Wakefield Cushman & Wakefield (NYSE: CWK) is a leading global commercial real estate services firm for property owners and occupiers with approximately 52,000 employees in nearly 400 offices and 60 countries. In Greater China, a network of 23 offices serves local markets across the region. In 2024, the firm reported revenue of $9.4 billion across its core services of Valuation, Consulting, Project & Development Services, Capital Markets, Project & Occupier Services, Industrial & Logistics, Retail, and others. Built around the belief that Better never settles, the firm receives numerous industry and business accolades for its award-winning culture. For additional information, visit or follow us on LinkedIn (


Al Etihad
2 days ago
- Al Etihad
Chinese sub discovers deepest-ever creatures 10 km undersea
30 July 2025 19:45 PARIS (AFP)A Chinese submersible has discovered thousands of worms and molluscs nearly 10 kilometres (six miles) below sea level in the Mariana Trench, the deepest colony of creatures ever observed, a study revealed on discovery in Earth's deepest underwater valley suggests that there could be much more life thriving in the hostile conditions at the bottom of our planet's largely unexplored oceans than previously thought, the China-led team of scientists all life on Earth is supported by light from the Sun. However in the total darkness at the bottom of the world, these creatures live off of chemicals such as methane seeping through cracks in the seafloor, a process called year, the Chinese submersible "Fendouzhe" -- or "Striver" -- dove 23 times into the depths of the Mariana Trench in the western Pacific Ocean with researchers on board, according to the study in the journal found colonies of thousands of marine tubeworms and molluscs called bivalves at depths ranging from 2,500 to 9,533 metres (8,200 to 31,000 feet) released alongside the study showed fields of tubeworms, which grew up to 30 centimetres (12 inches) long, as well as piles of molluscs and crustaceans, free-floating marine worms, sea cucumbers, feathery-armed sea lilies and other invertebrates were also recorded in the study marked "the discovery of the deepest and the most extensive chemosynthesis-based communities known to exist on Earth," its authors that other ocean trenches are similar, "such chemosynthesis-based communities might be more widespread than previously anticipated," they researchers said they also found "compelling evidence" that methane was being produced by microbes, with the tubeworms tending to cluster around microbial mats that resemble studies have found thriving communities of single-cell organisms on the ocean floor, but few large a remotely operated vehicle discovered tubeworms and other marine invertebrates living in hydrothermal vents in the crust below the seafloor two kilometres deep in the Pacific, research said last new study was published as nations wrangle over the contentious issue of deep-sea mining. China, the United States and others have expressed interest in mining the depths for valuable scientists warn that mining the little-explored seafloor, one of the last wild zones on the planet, could decimate fragile ecosystems that are not yet well recent talks, the International Seabed Authority -- which oversees deep-sea mining in international waters -- has yet to adopt long-awaited rules governing the media has previously reported that the Fendouzhe submersible mission will conduct research on "deep-sea materials".Only a handful of people have ever visited the bottom of the Mariana Trench, which is a crescent-shaped depression in the Earth's crust that is deeper than Mount Everest is first explorers visited the trench in 1960 on a brief after that, there were no missions until Hollywood director James Cameron made the first solo trip to the bottom in 2012, describing a "desolate" and "alien" environment. The water pressure at the bottom of the trench is a crushing eight tons per square inch, more than a thousand times the atmospheric pressure at sea level.


Gulf Today
7 days ago
- Gulf Today
NIH budget cuts are a setback for American science
White House budgets, generally speaking, aren't serious governing documents. Even so, they're a declaration of national priorities — and by that measure, the latest blueprint is deeply troubling. What sort of administration aspires to shrink its budget for scientific discovery by 40%? Health and Human Services Secretary Robert F. Kennedy Jr. recently testified before a House committee to defend cuts at the National Institutes of Health, the world's biggest funder of biomedical and behavioral research, according to the Tribune News Service. The agency going forward 'will focus on essential research at a more practical cost,' the secretary said. His plan would end taxpayer support for 'wasteful' academic areas, including certain gender-related topics. It's fair for the administration to set its own research priorities. But one would expect such cuts to free up (if not increase) funding for other urgent concerns, including chronic disease. Confoundingly, Kennedy appears intent on shrinking the entire research enterprise, thereby jeopardizing the White House's stated goals of improving public health, maintaining global leadership in science and staying ahead of China, which is set on closing the gap. His proposal also undermines the core principle that science is a vehicle for national progress. America's explicit commitment to support scientific research began in 1945. Inspired by wartime innovations, President Franklin D. Roosevelt asked his top science adviser to develop a program that would advance medicine, boost the economy and develop a cadre of young researchers. The resulting framework established science as a 'proper concern of government' and sought to reward academic inquiry with generous public funding. For the better part of a century, this formula worked quite well. The NIH enthusiastically funded basic research — largely through universities — and innovation bloomed. NIH grants have supported countless lifesaving advances, from cancer treatments and gene therapies to vaccines and diagnostic equipment. Almost a fifth of Nobel Prizes have been awarded to NIH scientists or grantees. Yet several factors have sown doubt about this model in recent years. Reports that the NIH supported Chinese research on coronaviruses, a type of which caused the COVID-19 pandemic, inflamed the public and increased scrutiny over grants writ large. Some lawmakers started to question whether the current system overwhelmingly favors established insiders to the detriment of promising junior scientists. Others raised doubts that elite universities — with their swelling administrative costs, staggering tuition rates and contentious ideological fixations — are prudent stewards of taxpayer dollars. For these reasons, the White House isn't wrong to scrutinize how universities spend federal money. A reassessment of the NIH's decades-old grant framework would be salutary. The process undoubtedly would benefit from including reviewers with more diverse professional backgrounds by, say, offering stronger incentives to participate. (The tiny stipends involved hardly compensate for the work required.) Ensuring more equitable distribution of grants among top applicants (for example, via lottery or 'golden ticket' allocations) would make sense, as would more generous funding for high-risk, high-reward research. Alas, such reforms don't appear to be what Kennedy has in mind. Instead of limiting some costs to improve systems and expand funds for critical research, the health secretary is seeking to issue 15,000 fewer grants by next year. In so doing, he threatens to impede crucial medical studies, shrink the number of new drugs and put American scientists at a needless disadvantage — all while China lavishly invests in research facilities, improves clinical trials and streamlines regulatory approvals. Congressional appropriations ultimately will determine what gets funded — and judging by recent hearings, lawmakers are deeply skeptical about Kennedy's budget. By expanding support for science and encouraging careful oversight, Congress can do its part to redirect the secretary's ambitions. It unfortunately bears emphasizing that diminishing science sends the wrong signal about America's trajectory, to its citizens and to the world.